Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report
Abstract Background Sodium valproate is a commonly used anticonvulsant. It is widely recognized that valproate can cause hyperammonemia, particularly in people with underlying liver disease. Patients with urea cycle disorders are genetically predisposed to this adverse event and can develop severe h...
Main Authors: | Shaine Mehta, Sarrah Tayabali, Robin Lachmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13256-018-1666-3 |
Similar Items
-
The menacing side of valproate: A case series of valproate-induced hyperammonemia
by: Deeksha Elwadhi, et al.
Published: (2017-01-01) -
A Case Series of Severe Hyperammonemia Encephalopathy Related to Valproate: Can Antipsychotics Increase the Risk?
by: Effat Davoudi-Monfared, et al.
Published: (2019-07-01) -
Valproate Metabolites and Hyperammonemia
by: J Gordon Millichap
Published: (1992-07-01) -
Use of carglumic acid in valproate‐induced hyperammonemia: 25 pediatric cases
by: Laura María Palomino Pérez, et al.
Published: (2020-09-01) -
Valproate-induced Hyperammonemic Encephalopathy
by: Hsiao-Feng Chou, et al.
Published: (2008-10-01)